We're building a better ClinicalTrials.gov. Check it out and tell us what you think!

Key Record Dates

ClinicalTrials.gov Identifier: NCT05117008
Brief Title: Maintenance Belantamab Mafodotin (Blenrep®) After B-cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed and/or Refractory Multiple Myeloma (EMBRACE)

First Submitted : November 2, 2021
First Submitted that Met QC Criteria : November 2, 2021
First Posted : November 11, 2021

Last Update Submitted that Met QC Criteria : August 3, 2022
Last Update Posted : August 4, 2022